Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study.
Saved in:
| Title: | Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study. |
|---|---|
| Authors: | Grenfell RFQ; Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil.; Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, United States., Almeida NBF; Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil.; Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, United States., Filgueiras PS; Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil., Corsini CA; Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil., Gomes SVC; Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil., de Miranda DAP; Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil., Lourenço AJ; Hospital da Baleia, Benjamin Guimarães Foundation, Belo Horizonte, Brazil., Martins-Filho OA; Grupo Integrado de Pesquisa em Biomarcadores, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil., de Oliveira JG; Laboratório de Imunologia Celular e Molecular, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil., Teixeira-Carvalho A; Grupo Integrado de Pesquisa em Biomarcadores, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil., Campos GRF; Laboratório de Pesquisas em Virologia (LPV), Faculdade de Medicina de São José do Rio Preto (FAMERP)São José do Rio Preto, São José do Rio Preto, Brazil., Nogueira ML; Laboratório de Pesquisas em Virologia (LPV), Faculdade de Medicina de São José do Rio Preto (FAMERP)São José do Rio Preto, São José do Rio Preto, Brazil.; Hospital de Base, São José do Rio Preto, Brazil.; Department of Pathology, University of Texas Medical Branch, Galveston, TX, United States., Alves PA; Imunologia de Doenças Virais, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil., Fernandes GR; Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil.; Biosystems Informatics, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil., Castilho LR; Cell Culture Engineering Laboratory (COPPE), Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Lima TM; Cell Culture Engineering Laboratory (COPPE), Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., de Abreu DPB; Cell Culture Engineering Laboratory (COPPE), Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Alvim RGF; Cell Culture Engineering Laboratory (COPPE), Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Silva TBS; Imunologia de Doenças Virais, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil., Jeremias WJ; Laboratório de farmacologia experimental, College of Pharmacy, Universidade Federal de Ouro Preto, Ouro Preto, Brazil., Otta DA; Grupo Integrado de Pesquisa em Biomarcadores, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil., Campi-Azevedo AC; Grupo Integrado de Pesquisa em Biomarcadores, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil. |
| Corporate Authors: | Immunita-001 Team |
| Source: | Frontiers in immunology [Front Immunol] 2022 Jun 09; Vol. 13, pp. 918896. Date of Electronic Publication: 2022 Jun 09 (Print Publication: 2022). |
| Publication Type: | Clinical Trial, Phase IV; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2022.918896 |
